1. Home
  2. News
  3. Avecho Biotechnology Limited
  4. Avecho licenses TPM for use in cancer drugs
More Avecho Biotechnology Limited news
Avecho Biotechnology LimitedASX: AVE

Avecho licenses TPM for use in cancer drugs

May 22, 2023 at 12:01 AM EDT · Issued by Avecho Biotechnology Limited

Filed with ASX · May 22, 2023 at 12:01 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/avecho-licenses-tpm-for-use-in-cancer-drugs

Avecho Biotechnology Limited on 6ix

In the deck

  • Avecho Biotechnology — Shareholder Meeting (May 2023)21 slidesMay 23, 2023

Earlier from Avecho Biotechnology

  • AVE commences manufacturing for Phase III trialMay 16, 2023
  • Results of Entitlement OfferMay 8, 2023
  • March 2023 Quarterly Activities Report & Appendix 4CApr 27, 2023
  • Investor PresentationApr 3, 2023
  • ProspectusApr 3, 2023

Later from Avecho Biotechnology

  • USPTO allows new TPM manufacturing patentMay 28, 2023
  • AVE adds TPM cannabinoid gummies to portfolioJun 6, 2023
  • AVE CBD capsule passes two-year stability milestoneJun 21, 2023
  • June 2023 Quarterly Activities Report & Appendix 4CJul 24, 2023
  • Voluntary SuspensionAug 24, 2023
All Avecho Biotechnology news releases↗

Follow Avecho Biotechnology into a list and get an email when it puts out news.

Follow Avecho Biotechnology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer